Star Scientific , Inc.'s Rock Creek Pharmaceuticals Subsidiary Enrolls First Alzheimer's Study Patient at Roskamp Institute
8/24/2012 11:26:29 AM
More...
|
Rock Creek Pharmaceuticals Release: Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
5/9/2012 9:32:32 AM
More...
|
Roskamp Institute Release: Key Clinical Trial of Alzheimer’s Disease Drug Begins in Europe
2/14/2012 8:57:18 AM
More...
|
Roskamp Institute Studies May Lead to Better Diagnosis and Eventual Treatment of Traumatic Brain Injuries
11/8/2011 9:41:52 AM
More...
|
Alzheimer’s Disease Drug Developed at Roskamp Institute Approved for Key Clinical Trial Funding in Europe
5/25/2011 9:40:22 AM
More...
|
Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceuticals RCP-006 Compound
2/28/2011 8:27:24 AM
More...
|
Star Scientific , Inc. Comments on Roskamp Institute's Plans to Conduct Human Alzheimer's Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
10/7/2010 11:05:26 AM
More...
|
Star Scientific , Inc. Announces Collaboration with Roskamp Institute on Beta-amyloid Discovery and Alzheimer's Disease
4/7/2010 10:40:52 AM
More...
|